Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Abnormal Cytokinesis in Cells Deficient in the Breast Cancer Susceptibility Protein BRCA2
Matthew J. Daniels,*Yunmei Wang,*MiYoung Lee,Ashok R. Venkitaraman
Germ-line mutations inactivating BRCA2 predispose to cancer.BRCA2-deficient cells exhibit alterations in chromosome number(aneuploidy), as well as structurally aberrant chromosomes.Here, we show that BRCA2 deficiency impairs the completion ofcell division by cytokinesis. BRCA2 inactivation in murine embryofibroblasts (MEFs) and HeLa cells by targeted gene disruptionor RNA interference delays and prevents cell cleavage. Impededcell separation is accompanied by abnormalities in myosin IIorganization during the late stages in cytokinesis. BRCA2 mayhave a role in regulating these events, as it localizes to thecytokinetic midbody. Our findings thus link cytokinetic abnormalitiesto a hereditary cancer syndrome characterized by chromosomalinstability and may help to explain why BRCA2-deficient tumorsare frequently aneuploid.
University of Cambridge, Cancer Research UK, Department of Oncology and the Medical Research Council (MRC) Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK.
* These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail: arv22{at}cam.ac.uk
Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers.
L. Tryggvadottir, L. Vidarsdottir, T. Thorgeirsson, J. G. Jonasson, E. J. Olafsdottir, G. H. Olafsdottir, T. Rafnar, S. Thorlacius, E. Jonsson, J. E. Eyfjord, et al. (2007)
J Natl Cancer Inst
99, 929-935
|Abstract »|Full Text »|PDF »
Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models.
Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility.
A. R. Lindh, S. Rafii, N. Schultz, A. Cox, and T. Helleday (2006)
Hum. Mol. Genet.
15, 1217-1224
|Abstract »|Full Text »|PDF »
Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency.
S. Beetstra, C. Salisbury, J. Turner, M. Altree, R. McKinnon, G. Suthers, and M. Fenech (2006)
Carcinogenesis
27, 517-524
|Abstract »|Full Text »|PDF »
A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan.
X. Wang, X. Wu, Z. Liang, Y. Huang, M. Fenech, and J. Xue (2006)
Mutagenesis
21, 41-47
|Abstract »|Full Text »|PDF »
BRCA1 Regulates RAD51 Function in Response to DNA Damage and Suppresses Spontaneous Sister Chromatid Replication Slippage: Implications for Sister Chromatid Cohesion, Genome Stability, and Carcinogenesis.
I. Cousineau, C. Abaji, and A. Belmaaza (2005)
Cancer Res.
65, 11384-11391
|Abstract »|Full Text »|PDF »
Invited Review: Bovine Milk Fat Globule Membrane as a Potential Nutraceutical.
Functional Evaluation and Cancer Risk Assessment of BRCA2 Unclassified Variants.
K. Wu, S. R. Hinson, A. Ohashi, D. Farrugia, P. Wendt, S. V. Tavtigian, A. Deffenbaugh, D. Goldgar, and F. J. Couch (2005)
Cancer Res.
65, 417-426
|Abstract »|Full Text »|PDF »